Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...
Craig Berube ended his forward experiment early against the Vancouver Canucks and revealed why he broke things up. Do the ...
Toronto Maple Leafs head coach Craig Berube broke up the William Nylander, John Tavares, and Mitch Marner second line, and it ...
The Massachusetts Bay Transportation Authority will launch South Coast Rail operations — serving a group of southeastern ...
Insmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its ...
After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...
Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...
Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...
About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company’s drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback